Marker for cancer prognosis and methods related thereto
OwnerAftab Ahmad, Carl W. Whiteinventors
Life of this patent
Estimating the term…
Abstract
The present invention is related to the novel discovery that HIF-2α, but not HIF-1α, selectively regulates adenosine A2A receptor in endothelial cells, thereby revealing a unique and hitherto unknown pathway by which HIF-2α can regulate angiogenesis independent of HIF-1α. This discovery allows for design of new diagnostic tools and novel therapies targeted against angiogenesis-associated diseases, such as cancer. In another aspect, the present invention shows that A2A receptor expression is a marker of the developing lung, and can be used as a marker of lung diseases, such as pulmonary hypertension.
Claims11
A method to diagnose a patient with a cancer that is associated with HIF-2α expression, comprising:
- a) detecting the expression of adenosine A2A receptor (A2A) in a sample of tumor cells from a patient;
- b) comparing the level of expression of A2A detected in the patient sample to a level of expression of A2A in a non-tumor cell control sample;
- and
- c) diagnosing the patient as having a cancer that is associated with HIF-2α, if the expression level of A2A in the patient's tumor cells is statistically higher than the expression level of A2A in the non-tumor cell control.
(canceled)
A method to identify cancer patients with a high level of tumor aggressiveness, comprising:
- a) detecting the expression of adenosine A2A receptor (A2A) in a sample of tumor cells from a patient;
- b) comparing the level of expression of A2A detected in the patient sample to a level of expression of A2A in a non-tumor cell control sample;
- and
- c) selecting the patient as having a high level of tumor aggressiveness, if the expression level of A2A in the patient's tumor cells is statistically higher than the expression level of A2A in the non-tumor cell control.
A method to select a cancer patient who is predicted to benefit from therapeutic administration of a HIF-2α antagonist, an agonist thereof, or a drug having substantially similar biological activity as the HIF-2α antagonist, comprising:
- a) detecting the expression of adenosine A2A receptor (A2A) in a sample of tumor cells from a patient;
- b) comparing the level of expression of A2A detected in the patient sample to a level of expression of A2A in a non-tumor cell control sample;
- and
- c) selecting the patient as being predicted to benefit from therapeutic administration of the HIF-2α antagonist, if the expression level of A2A in the patient's tumor cells is statistically higher than the expression level of A2A in the non-tumor cell control.
(canceled)
11-20. (canceled)
Dependencies are inferred from the claim text.